CytoMed Therapeutics Limited

GDTC Healthcare Biotechnology

CytoMed Therapeutics Limited’s revenue for fiscal 2025 (year ended December 2025) was $252,300.00, up 395.7% from fiscal 2024. Insiders bought in the last twelve months.

0.88 0.01 +1.15%
Market cap
$10.3M
P/E
0.0×
Fwd P/E
−13.6×
Dividend yield
—
F-score
n/a
Altman Z
6.84
Beneish M
0.11
Dividend safety
n/a
Jun '26 Dec '25 Jun '25 Dec '24 Older periods
ROE
0.00% 0.00% 0.00% 0.00%

+7 more TTM periods

ROA
0.00% 0.00% 0.00% 0.00%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
0.00% 0.00% 0.00% 0.00%
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
— 0.00 0.00 0.00
Free Cash Flow
— (9.19) (8.47) (8.45)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026